deltatrials
Completed PHASE3 NCT00002760

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTAGE CANCER

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Prostate Cancer
Interventions Withdrawal of antiandrogen therapy ketoconazole therapeutic hydrocortisone
Updated 6 times since 2017 Last updated: Jun 27, 2016 Started: Aug 31, 1996 Primary completion: Mar 31, 2004 Completion: Apr 30, 2009

This PHASE3 trial investigates Prostate Cancer and is currently completed. Alliance for Clinical Trials in Oncology leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Minneapolis, United States
  • • San Francisco, United States